| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Departments of Medical Biophysics*
and Medical
Oncology,
Sunnybrook Health Science Centre,
University of Toronto, Toronto, Ontario, Canada, and the Departments of
Tumor Biology
and
Pathology,§
Institute for Cancer Research, The
Norwegian Radium Hospital, Oslo, Norway
In the present study we analyzed, by immunohistochemistry, a panel of human melanomas for protein expression of the cyclin-dependent kinase (cdk) inhibitor p27Kip1 and evaluated whether deregulated expression correlates with clinical outcome for this type of cancer. We found that p27Kip1 was strongly expressed by normal melanocytes and benign nevi, whereas in malignant melanoma, a heterogeneous expression pattern was observed. In the case of nodular melanomas, the level of p27Kip1 was found to correlate significantly with the thickness of the tumor, with less protein expressed in thicker lesions. We also found that patients having tumors with fewer than 5% p27Kip1-staining cells had a significantly higher risk of early relapse of their disease compared with those expressing moderate or high levels. In contrast, the level of p27Kip1 did not correlate with tumor thickness or disease-free survival in patients with superficial spreading melanomas, suggesting that p27Kip1 may play different roles in these two major pathological subgroups of malignant melanoma. Furthermore, p27Kip1 did not appear to have an influence on overall survival for either subgroup. When we examined the combined effect of p21WAF1/CIP1 (another cdk inhibitor) and p27Kip1 on clinical outcome, we found that analysis of these two cdk inhibitors together may have greater prognostic potential than either alone. In conclusion, our results suggest that virtually complete loss of p27Kip1 protein expression has potential importance as a prognostic indicator of early relapse in patients with nodular melanoma. The results, furthermore, underscore the value of analyzing multiple cell cycle regulatory proteins to obtain the most reliable indication of prognosis.
This article has been cited by other articles:
 |
|
 |
|
  F. Felicetti, M. C. Errico, L. Bottero, P. Segnalini, A. Stoppacciaro, M. Biffoni, N. Felli, G. Mattia, M. Petrini, M. P. Colombo, et al. The Promyelocytic Leukemia Zinc Finger-MicroRNA-221/-222 Pathway Controls Melanoma Progression through Multiple Oncogenic Mechanisms Cancer Res., April 15, 2008; 68(8): 2745 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-C. Chang, F.-R. Chang, Y.-C. Wang, M.-R. Pan, W.-C. Hung, and Y.-C. Wu A bioactive withanolide Tubocapsanolide A inhibits proliferation of human lung cancer cells via repressing Skp2 expression Mol. Cancer Ther., May 1, 2007; 6(5): 1572 - 1578. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Carreira, J. Goodall, L. Denat, M. Rodriguez, P. Nuciforo, K. S. Hoek, A. Testori, L. Larue, and C. R. Goding Mitf regulation of Dia1 controls melanoma proliferation and invasiveness Genes & Dev., December 15, 2006; 20(24): 3426 - 3439. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Liu, J. P. Dowling, W. K. Murray, G. A. McArthur, J. F. Thompson, R. Wolfe, and J. W. Kelly Rate of Growth in Melanomas: Characteristics and Associations of Rapidly Growing Melanomas Arch Dermatol, December 1, 2006; 142(12): 1551 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. E. A. LaRue, M. Khalil, and J. P. Freyer Microenvironmental Regulation of Proliferation in Multicellular Spheroids Is Mediated through Differential Expression of Cyclin-Dependent Kinase Inhibitors Cancer Res., March 1, 2004; 64(5): 1621 - 1631. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Ghanem, T. H. Van der Kwast, M. K. Sudaryo, R. B. Mathoera, M. M. van den Heuvel, A.-A. M. Al-Doray, R. M. Nijman, and G. J. van Steenbrugge MIB-1 (KI-67) Proliferation Index and Cyclin-Dependent Kinase Inhibitor p27Kip1 Protein Expression in Nephroblastoma Clin. Cancer Res., January 15, 2004; 10(2): 591 - 597. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Alonso, P. Ortiz, M. Pollan, B. Perez-Gomez, L. Sanchez, M. J. Acuna, R. Pajares, F. J. Martinez-Tello, C. M. Hortelano, M. A. Piris, et al. Progression in Cutaneous Malignant Melanoma Is Associated with Distinct Expression Profiles: A Tissue Microarray-Based Study Am. J. Pathol., January 1, 2004; 164(1): 193 - 203. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Jorgensen, R. Holm, G. M. Maelandsmo, and V. A. Florenes Expression of Activated Extracellular Signal-Regulated Kinases 1/2 in Malignant Melanomas: Relationship with Clinical Outcome Clin. Cancer Res., November 1, 2003; 9(14): 5325 - 5331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. M. Maelandsmo, R. Holm, J. M. Nesland, O. Fodstad, and V. A. Florenes Reduced {beta}-Catenin Expression in the Cytoplasm of Advanced-Stage Superficial Spreading Malignant Melanoma Clin. Cancer Res., August 1, 2003; 9(9): 3383 - 3388. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sui, Y. Dong, M. Ohno, Y. Watanabe, K. Sugimoto, Y. Tai, and M. Tokuda Jab1 Expression Is Associated with Inverse Expression of p27kip1 and Poor Prognosis in Epithelial Ovarian Tumors Clin. Cancer Res., December 1, 2001; 7(12): 4130 - 4135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Hommura, H. Dosaka-Akita, T. Mishina, M. Nishi, T. Kojima, H. Hiroumi, S. Ogura, M. Shimizu, H. Katoh, and Y. Kawakami Prognostic Significance of p27KIP1 Protein and Ki-67 Growth Fraction in Non-small Cell Lung Cancers Clin. Cancer Res., October 1, 2000; 6(10): 4073 - 4081. [Abstract] [Full Text]
|
|
|
|
 |
|
 F. Mouriaux, C.-A. Maurage, P. Labalette, B. Sablonnière, F. Malecaze, and J.-M. Darbon Cyclin-Dependent Kinase Inhibitory Protein Expression in Human Choroidal Melanoma Tumors Invest. Ophthalmol. Vis. Sci., September 1, 2000; 41(10): 2837 - 2843. [Abstract] [Full Text]
|
|
|
|
|
|
V. A. Flørenes, R. S. Faye, G. M. Mælandsmo, J. M. Nesland, and R. Holm Levels of Cyclin D1 and D3 in Malignant Melanoma: Deregulated Cyclin D3 Expression Is Associated with Poor Clinical Outcome in Superficial Melanoma Clin. Cancer Res., September 1, 2000; 6(9): 3614 - 3620. [Abstract] [Full Text]
|
|
|
|
 |
|
 A. M. Oliveira, A. G. Nascimento, S. H. Okuno, and R. V. Lloyd p27kip1 Protein Expression Correlates With Survival in Myxoid and Round-Cell Liposarcoma J. Clin. Oncol., August 15, 2000; 18(15): 2888 - 2893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Pruneri, L. Pignataro, N. Carboni, R. Buffa, D. Di Finizio, B. M. Cesana, and A. Neri Clinical Relevance of Expression of the CIP/KIP Cell-Cycle Inhibitors p21 and p27 in Laryngeal Cancer J. Clin. Oncol., October 1, 1999; 17(10): 3150 - 3159. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Baekelandt, R. Holm, C. G. Trope, J. M. Nesland, and G. B. Kristensen Lack of Independent Prognostic Significance of p21 and p27 Expression in Advanced Ovarian Cancer: An Immunohistochemical Study Clin. Cancer Res., October 1, 1999; 5(10): 2848 - 2853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Lloyd, L. A. Erickson, L. Jin, E. Kulig, X. Qian, J. C. Cheville, and B. W. Scheithauer p27kip1: A Multifunctional Cyclin-Dependent Kinase Inhibitor with Prognostic Significance in Human Cancers Am. J. Pathol., February 1, 1999; 154(2): 313 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. E. Clurman and P. Porter New insights into the tumor suppression function of P27Kip1 PNAS, December 22, 1998; 95(26): 15158 - 15160. [Full Text] [PDF]
|
|
|
|
 |
|
 H.-Y. Yang, B. P. Zhou, M.-C. Hung, and M.-H. Lee Oncogenic Signals of HER-2/neu in Regulating the Stability of the Cyclin-dependent Kinase Inhibitor p27 J. Biol. Chem., August 4, 2000; 275(32): 24735 - 24739. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
